Relationships Among Heart Rate, β-Blocker Dosage, and Prognosis in Patients With Coronary Artery Disease in a Real-World Database Using a Multimodal Data Acquisition System
-
- Oba Yusuke
- Jichi Medical University School of Medicine
-
- Kabutoya Tomoyuki
- Jichi Medical University School of Medicine
-
- Kohro Takahide
- Jichi Medical University School of Medicine
-
- Imai Yasushi
- Jichi Medical University School of Medicine
-
- Kario Kazuomi
- Jichi Medical University School of Medicine
-
- Sato Hisahiko
- Precision Inc.
-
- Nochioka Kotaro
- Tohoku University
-
- Nakayama Masaharu
- Tohoku University
-
- Fujita Hideo
- Jichi Medical University Saitama Medical Center
-
- Mizuno Yoshiko
- The University of Tokyo Development Bank of Japan
-
- Kiyosue Arihiro
- The University of Tokyo
-
- Iwai Takamasa
- National Cerebral and Cardiovascular Center
-
- Miyamoto Yoshihiro
- National Cerebral and Cardiovascular Center
-
- Nakano Yasuhiro
- Kyushu University
-
- Nakamura Taishi
- Kumamoto University
-
- Tsujita Kenichi
- Kumamoto University
-
- Matoba Tetsuya
- Kyushu University
-
- Nagai Ryozo
- Jichi Medical University School of Medicine
この論文をさがす
抄録
<p>Background: The optimal heart rate (HR) and optimal dose of β-blockers (BBs) in patients with coronary artery disease (CAD) have been unclear. We sought to clarify the relationships among HR, BB dose, and prognosis in patients with CAD using a multimodal data acquisition system.</p><p>Methods and Results: We evaluated the data for 8,744 CAD patients who underwent cardiac catheterization from 6 university hospitals and the National Cerebral and Cardiovascular Center and who were registered using the Clinical Deep Data Accumulation System. Patients were divided into quartile groups based on their HR at discharge: Q1 (HR <60 beats/min), Q2 (HR 60–66 beats/min), Q3 (HR 67–74 beats/min), and Q4 (HR ≥75 beats/min). Among patients with acute coronary syndrome (ACS) and patients with chronic coronary syndrome (CCS), those in Q4 (HR ≥75 beats/min) had a significantly greater incidence of major adverse cardiac and cerebral events (MACCE) compared with those in Q1 (ACS patients: hazard ratio 1.65, P=0.001; CCS patients: hazard ratio 1.45, P=0.019). Regarding the use of BBs (n=4,964), low-dose administration was significantly associated with MACCE in the ACS group (hazard ratio 1.41, P=0.012), but not in patients with CCS after adjustment for covariates.</p><p>Conclusions: HR ≥75 beats/min was associated with worse outcomes in patients with CCS or ACS.</p>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 87 (2), 336-344, 2023-01-25
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390013408148467456
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 032636372
-
- PubMed
- 36216562
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
-
- 抄録ライセンスフラグ
- 使用不可